CER Daily Newsfeed

Safety-Net Providers Bought a Record $53.7B of Discounted Drugs: Report

(9/27, Adriel Bettelheim, Axios) reports “...Safety-net providers bought a record $53.7 billion worth of medicines under the federal drug discount program last year - a 22% jump over 2021 that came while drug price growth lagged behind overall inflation, according to a published report. Why it matters: The report in the trade publication Drug Channels draws into question claims from some program advocates that drugmakers' business practices are eroding the health care safety net.” Full

Real-World Evidence Analysis Must Protect Patient Privacy, FDA Says

(9/26, Jessica Karins, InsideHealthPolicy) reports “...FDA specifically says sponsors should have protocols in place to ensure patients’ privacy is protected and that source data can be shared with FDA. ‘When appropriate, sponsors should consult with experts who consider data privacy issues to provide input on the protocol as part of the study design process for a non-interventional study, as these experts may help identify and address data privacy and security concerns raised when accessing health care data,’ the guidance says.” Subscription Required

RWE Tips from Boston Scientific Peripheral Interventions CMO Dr. Michael Jaff

(9/26, Jim Hammerand, Medical Design & Outsourcing) reports “...‘By the time a randomized trial is completed and published, the technology is already several years old, because those trials take a long time. They’re on a very selected patient population — not the population that’s routinely managed by physicians, but a subgroup of those patients,’ Jaff said. ‘So as people who are developing new therapies are thinking about, “What’s my next strike opportunity? Where can I really go?” I would urge them to think about looking into real-world evidence to help guide them.’” Full

Payers, Providers Are Cautiously Optimistic about Their Value-based Care Efforts. Here's How Their Sentiments Differ

(9/26, Anastassia Gliadkovskaya, Fierce Healthcare) reports “...Most respondents thought their VBC programs had been somewhat successful in controlling costs, improving the patient experience and improving clinical outcomes. Less than half thought they were somewhat successful when it came to improving the provider experience. Notably fewer respondents thought their programs were very successful at addressing any of these areas.” Full

Video: Collaboration Is Key to Success in Alternative Payment Models, Says COA’s Nick Ferreyros

(9/27, Maggie L. Shaw, The American Journal of Managed Care) “The number one ingredient that an oncology-based alternative payment model (APM) need to succeed is collaboration, working with stakeholders, participants, and practices, explained Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.” View Video

UK: NICE Poised to Reject AstraZeneca, Daiichi’s Enhertu in HER2-Low Breast Cancer

(9/27, Angus Liu, Fierce Pharma) reports “...Enhertu is not recommended for National Health Service coverage for treating HER2-low metastatic or unresectable breast cancer after chemotherapy, the National Institute for Health and Care Excellence said in draft guidance. NICE’s opinion comes as a surprise given Enhertu’s impressive clinical data, which the agency recognized in its evaluation.” Full